최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기약학회지 = Yakhak hoeji, v.52 no.1, 2008년, pp.43 - 47
노아롱새미 (숙명여자대학교 약학대학) , 천링 (숙명여자대학교 약학대학) , 임미정 (숙명여자대학교 약학대학)
To determine the regulatory roles of PDE4 inhibitor on LPS-induced osteoclastogenesis, we investigated the effect of a PDE4 inhibitor on osteoclast formation in the presence of LPS. A specific PDE4 inhibitor, rolipram, increased LPS-induced osteoclast formation in cocultures. To verify that whether ...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
Takahashi, N., Akatsu, T., Udagawa, N., Sasaki, T., Yamaguchi, A., Moseley, J. M., Martin, T. J. and Suda, T. : Osteoblastic cells are involved in osteoclast formation. Endocrinology 123, 2600 (1988)
Suda, T., Takahashi, N., Udagawa, N., Jimi, E., Gillespie, M. T. and Martin, T. J. : Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20, 345 (1999)
Wong, B. R., Rho, J., Arron, J., Robinson, E., Orlinick, J., Chao, M., Kalachikov, S., Cayani, E., Bartlett, F. S. 3rd, Frankel, W. N., Lee, S. Y. and Choi, Y. : TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun Nterminal kinase in T cells. J. Biol. Chem. 272, 25190 (1997)
Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., Tsuda, E., Morinaga, T., Higashio, K., Udagawa, N., Takahashi, N. and Suda, T. : Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesisinhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 95, 3597 (1998)
Lacey, D. L., Timms, E., Tan, H. L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., Hsu, H., Sullivan, J., Hawkins, N., Davy, E., Capparelli, C., Eli, A., Qian, Y. X., Kaufman, S., Sarosi, I., Shalhoub, V., Senaldi, G., Guo, J., Delaney, J. and Boyle, W. J. : Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165 (1998)
Nair, S. P., Meghji, S., Wilson, M., Reddi, K., White, P. and Henderson, B. : Bacterially induced bone destruction: mechanisms and misconceptions. Infect Immun. 64, 2371 (1996)
Wang, P. L. and Ohura, K. : Porphyromonas gingivalis lipopolysaccharide signaling in gingival fibroblasts-CD14 and Toll-like receptors. Crit. Rev. Oral. Biol. Med. 13, 132 (2002)
Coon, D., Gulati, A., Cowan, C. and He, J. : The role of cyclooxygenase-2 (COX-2) in inflammatory bone resorption. J. Endod. 33, 432 (2007)
Sakuma, Y., Tanaka, K., Suda, M., Komatsu, Y., Yasoda, A., Miura, M., Ozasa, A., Narumiya, S., Sugimoto, Y., Ichikawa, A., Ushikubi, F. and Nakao, K. : Impaired bone resorption by lipopolysaccharide in vivo in mice deficient in the prostaglandin E receptor EP4 subtype. Infect Immun. 68, 6819 (2000)
Kaji, H., Sugimoto, T., Kanatani, M., Fukase, M., Kumegawa, M. and Chihara, K. : Prostaglandin $E_2$ stimulates osteoclastlike cell formation and bone-resorbing activity via osteoblasts: role of cAMP-dependent protein kinase. J. Bone Miner. Res. 11, 62 (1996)
Park, H., Young Lee, S., Lee, D. S. and Yim, M. : Phosphodiesterase 4 inhibitor regulates the TRANCE/OPG ratio via COX-2 expression in a manner similar to PTH in osteoblasts. Biochem. Biophys. Res. Commun. 354, 178 (2007)
Essayan, D. M. : Cyclic nucleotide phosphodiesterases. J. Allergy Clin. Immunol. 108, 671 (2001)
Bender, A. T. and Beavo, J. A. : Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol. Rev. 58, 488 (2006)
Jin, S. L., Lan, L., Zoudilova, M. and Conti, M. : Specific role of phosphodiesterase 4B in lipopolysaccharide-induced signaling in mouse macrophages. J. Immunol. 175, 1523 (2005)
Lagente, V., Martin-Chouly, C., Boichot, E., Martins, M. A. and Silva, P. M. : Selective PDE4 inhibitors as potent antiinflammatory drugs for the treatment of airway diseases. Mem. Inst. Oswaldo. Cruz. 100, Suppl 1:131 (2005)
Suda, K., Udagawa, N., Sato, N., Takami, M., Itoh, K., Woo, J. T., Takahashi, N. and Nagai, K. : Suppression of osteoprotegerin expression by prostaglandin $E_2$ is crucially involved in lipopolysaccharide-induced osteoclast formation. J. Immunol. 172, 2504 (2004)
Itoh, K., Udagawa, N., Kobayashi, K., Suda, K., Li, X., Takami, M., Okahashi, N., Nishihara, T. and Takahashi, N. : Lipopolysaccharide promotes the survival of osteoclasts via Toll-like receptor 4, but cytokine production of osteoclasts in response to lipopolysaccharide is different from that of macrophages. J. Immunol. 170, 3688 (2003)
Suda, K., Woo, J. T., Takami, M., Sexton, P. M. and Nagai, K. : Lipopolysaccharide supports survival and fusion of preosteoclasts independent of TNF-alpha, IL-1, and RANKL. J. Cell Physiol. 190, 101 (2002)
Yao, W., Tian, X. Y., Chen, J., Setterberg, R. B., Lundy, M. W., Chmielzwski, P., Froman, C. A. and Jee, W. S. : Rolipram, a phosphodiesterase 4 inhibitor, prevented cancellous and cortical bone loss by inhibiting endosteal bone resorption and maintaining the elevated periosteal bone formation in adult ovariectomized rats. J. Musculoskelet Neuronal Interact. 7, 119 (2007)
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
오픈액세스 학술지에 출판된 논문
※ AI-Helper는 부적절한 답변을 할 수 있습니다.